To evaluate the effects of chronic supplementation with a balanced short-chain fatty acid (SCFA) mixture on seizure progression, cognitive outcomes, and gut-brain integrity in a mouse model of drug-resistant epilepsy (DRE).
Approach:
Experimental Model: C57BL6N male young adult mice were subjected to status epilepticus induced by intra-amygdala kainate, followed by chronic EEG monitoring for seizure activity.
SCFA Treatment Protocol: Mice received a balanced SCFA mixture (40 mM Na butyrate, 26 mM propionate, and 67.5 mM acetate) in drinking water starting 5 hours after SE induction, compared to a vehicle control.
Key Findings:
SCFA supplementation significantly attenuated seizure progression in the mouse model.
Cognitive deficits were mitigated in SCFA-treated mice.
Histopathological changes in both the brain and gut were partially restored with SCFA treatment.
Metabolomic profiling indicated a multi-level modulatory effect of SCFAs on the gut-brain axis.
Interpretation:
The findings suggest that SCFAs may serve as a promising disease-modifying strategy for drug-resistant epilepsy, particularly in progressive forms.
Limitations:
The study was conducted in a mouse model, which may not fully replicate human epilepsy.
The long-term effects of SCFA supplementation beyond the study duration remain unknown.
Conclusion:
SCFAs show potential for influencing disease progression in drug-resistant epilepsy, warranting further investigation for clinical application.
